{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02965516",
  "id": "02965516",
  "pages": 1,
  "price_sensitive": false,
  "date": "20250703",
  "time": "0941",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250703/pdf/06lf4cshwnz5xf.pdf",
  "summary": "- **Operational Milestone**: Manufacturing commenced for lead product IRX-211, a proprietary inhaled cannabinoid for breakthrough cancer pain (BTcP).  \n- **Clinical Stage**: Preparation for upcoming fully funded Phase 2 trial.  \n- **Manufacturing Partner**: Ab Initio Pharma (GMP-certified).  \n- **Funding Facility**: Up to $38.5m secured for development of IRX-211 and IRX-616a (Panic Disorder).  \n\n*No material trading or capital markets impact identified (no new financing, timelines, or material data points).*",
  "usage": {
    "prompt_tokens": 876,
    "completion_tokens": 119,
    "total_tokens": 995,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-02T23:51:00.178579"
}